Windtree Therapeutics

A publicly traded clinical stage cardiovascular drug development company developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with its lead candidate, istaroxime, a Phase 2 molecule with FDA fast track designation being developed as a first-in-class treatment for acute heart failure and cardiogenic shock. Its heart failure platform includes follow-on oral preclinical SERCA2a activator assets as well. Another asset, rostafuroxin is a Phase 2b stage novel drug product targeting the treatment of resistant hypertension for patients with certain genetic profiles.